

# Clesrovimab Guide (Enflonsia - monoclonal antibody [mAb])

*To prevent severe respiratory syncytial virus (RSV) in infants younger than 8 months of age.*

Clesrovimab is recommended for use only in infants less than 8 months of age entering their first RSV season (usually October through March) who during pregnancy did not receive a prenatal RSV vaccine during 32-36 weeks gestation. Clesrovimab is administered to infants using the same dose regardless of weight. In rare circumstances, an infant may be recommended to receive clesrovimab after a prenatal RSV vaccination.

## If born October through March:

One dose within first week of birth.

## If born April through September:

One dose prior to the start of their first RSV season.

Or as soon as possible during the RSV season.

The recommended dose for neonates and infants born during or entering into their first RSV season is **105 mg administered as a 0.7mL single dose intramuscular (IM) injection.**